Showing results (201-210 of 6,499) with videos related to
Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|May 6, 2006
DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution methodStéphanie Delluc, Léa Tourneur, Didier Fradelizi, et al.Cancer Immunology, Immunotherapy : CII|April 14, 2006
A mechanistic study of immune system activation by fusion of antigens with the ligand-binding domain of CTLA4Dhanalakshmi Chinnasamy, Matt Tector, Nachimuthu Chinnasamy, et al.Cancer Immunology, Immunotherapy : CII|May 20, 2006
Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10Mingzhong Zheng, Dora Bocangel, Blair Doneske, et al.Cancer Immunology, Immunotherapy : CII|July 29, 2006
huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor modelsKin-Ming Lo, Yan Lan, Scott Lauder, et al.Cancer Immunology, Immunotherapy : CII|July 27, 2006
Guided selection of an anti-gamma-seminoprotein human Fab for antibody directed enzyme prodrug therapy of prostate cancerQing Zhang, Si-He Zhang, Ming-Quan Su, et al.Cancer Immunology, Immunotherapy : CII|August 15, 2006
An altered peptide ligand for naïve cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicityYan Tang, Zhihua Lin, Bing Ni, et al.Cancer Immunology, Immunotherapy : CII|August 29, 2006
Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis modelPetra Lutterbuese, Klaus Brischwein, Robert Hofmeister, et al.Cancer Immunology, Immunotherapy : CII|September 13, 2006
Tumor specific phage particles promote tumor regression in a mouse melanoma modelFredrik Eriksson, W David Culp, Robert Massey, et al.Cancer Immunology, Immunotherapy : CII|April 26, 2006
Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surfaceJeannette Gerspach, Julia Németh, Sabine Münkel, et al.Cancer Immunology, Immunotherapy : CII|August 10, 2006
Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusionFlavia Brunstein, Saske Hoving, Gisela aan de Wiel-Ambagtsheer, et al.Pageof 650